Previous 10 | Next 10 |
Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer abuse-deterrent transdermal patches ORLANDO, FL / ACCESSWIRE / March 25, 2024 / ...
Nutriband Inc. (NASDAQ: NTRB) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 9.76% on the day to $2.7. Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in developmen...
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be present...
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30 th through February 1 st . ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference taking plac...
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The full text of th...
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentan...
2023-12-18 11:52:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nutriband (NASDAQ: NTRB ) just reported results for the third quarter of 2023. Nutriband reported earnings per share of -22 cents. The company reported revenue of $427...
First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q3 2023 GEA Group AG (GEAGF) is expected to report for Q3 2023 Janel Corp (JANL) is expected to report for quarter end 2023-09-30 Screen Holdings Co. Ltd. (DINRF) is expected to report for Q2 2024 Tom...
Tomra Systems ASA ADR (TMRAY) is expected to report for Q3 2023 China Minsheng Banking Corporation Ltd. ADR (CMAKY) is expected to report for quarter end 2023-09-30 Taisei Corporation ADR (TISCY) is expected to report for Q2 2024 Spark New Zealand Limited ADR (SPKKY) is expected to re...
ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence (AI Tape) Brand portfolio. AI Tape Heating...
News, Short Squeeze, Breakout and More Instantly...
Nutriband (NASDAQ: NTRB) , a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and Preside...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Cha...
Nutriband (NASDAQ: NTRB) , a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registrat...